BioHub at Alderley Park, operated by life science incubation specialist, The BioCity Group, supports the creation and growth of successful life science companies. This is achieved by creating the optimum environment for emerging businesses to thrive by offering 86,000sq ft of world class state-of-the-art laboratories and commercial office space, shared services, training, business support and access to investment. An absolute must for you BioTech startups!


“The BioHub at Alderley Park enables emerging pharmaceutical, biotech and life science companies to take advantage of some of the UK’s best invested research and development facilities, scientific heritage and industry experts, while operating entirely independently. The success of this formula is supported by the 91% survival rate of BioCity-based companies over 12 years.”


Standard Package: Hot desk space, incoming & outgoing mail services, professional reception services, free onsite parking, company name in reception, communal social and meeting spaces within the atrium, meeting rooms to hire at competitive rates, a dedicated page on the BioCity/BioHub website, with links to products and to your company site, access to specialist business support services, invitations to closed BioCity/BioHub events, subscription private BioCity community newsletters and intranet

£85/month (exc. VAT)

Advanced Package: Everything from the Standard Package, dedicated lockable desk and cabinet, dedicated phone line at a minimal cost.

£150/month (exc. VAT)


Example companies


Facts for Life

Facts for Life are a niche educational provider of scientific enrichment programmes, with a track record in developing a deeper breadth of knowledge that empowers students to make informed life choices.

Cyprotex

Cyprotex specialises in preclinical ADMET services utilising both in vitro and in silico technologies and is based both in the UK and USA.

Absynth Biologics Ltd

Absynth Biologics discovers and develops vaccines and antibodies to prevent and treat bacterial infections based on proprietary, non-conventional platform for identifying novel protein antigen that harness the immune system and that use a dual-action mechanism.